-
Application of third-generation EGFR-TKI in EGFRm NSCLC treatment (Part I)
Time of Update: 2022-11-15
The results of the FLAURA study showed that in patients with baseline with brain metastases, mPFS in patients receiving osimertinib was significantly prolonged compared with first-generation EGFR-TKI (15.
-
Professor He Pengcheng: Through the fog, the innovative ADC drug Pola continues hope for DLBCL patients with CAR-T treatment failure
Time of Update: 2022-11-15
Figure 5 Real-world research in the UKIn summary, the Pola combination regimen has reliable efficacy, no safety concerns such as specific CRS, and the convenient application of ready-to-use drugs, which provides a new treatment option for patients with R/R DLBCL and CAR-T therapy failure.
-
Interview with Professor Ma Fei|: Interpretation of the highlights of the new version of the "Guidelines for the Standardized Diagnosis and Treatment of Advanced Breast Cancer in China" - standardized, innovative and leading, which is more in line with China's national conditions
Time of Update: 2022-11-15
A few days ago, the "Guidelines for the Standardized Diagnosis and Treatment of Advanced Breast Cancer in China (2022 Edition)" (hereinafter referred to as the "Guidelines") jointly compiled by the Br
-
Professor Wang Jianxiang: Selinisol takes into account both efficacy and safety, bringing a new option for dual-optimal treatment for AML patients
Time of Update: 2022-11-15
Acute myeloid leukemia (AML) is a malignant clonal disease derived from hematopoietic stem cells, which tends to occur in the elderly, with a median age of onset of 66 years, and the incidence increas
-
This article reviews the research status and future of KRAS-targeted therapy in the field of RAS pathway and lung cancer
Time of Update: 2022-11-15
Table 1 Selected KRAS-targeted therapiesClinically used KRAS G12C inhibitorPhase I/II CodeBreaK 100 Study – Preliminary human trial data from 22 patients with advanced KRAS G12C-mutant solid tumors receiving sotorasib showed monotherapy antitumor activity.
-
Dual-target combination, composing music for "raw" Domestic trastuzumab combined with pertuzumab neoadjuvant therapy to win the "breast defense battle" for young breast cancer patients
Time of Update: 2022-11-15
Initial diagnosis: invasive carcinoma of the right breast, grade IIIAfter treatmentNeoadjuvant therapy: patients received a six-cycle "docetaxel + carboplatin + trastuzumab + pertuzumab" (TCbHP) regimen from 2021-10 to 2022-3.
-
Immunotherapy options for mantle cell lymphoma progressing after BTK inhibitor therapy
Time of Update: 2022-11-15
Over the past decade, Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment and management of recurrent mantle cell lymphoma (MCL). BTK inhibitors such as ibrutinib, acalabrutinib,
-
Trop2 ADC drug competition: who will be better
Time of Update: 2022-11-15
Meanwhile, a phase II clinical trial (NCT05351788) began evaluating the antitumor activity of SKB264 in combination with KL-A167 in advanced or metastatic non-small cell lung cancer.
Meanwhile, a phase II clinical trial (NCT05351788) began evaluating the antitumor activity of SKB264 in combination with KL-A167 in advanced or metastatic non-small cell lung cancer.
-
5-year EFS rate 95.2%, 5-year OS rate 100%! Rituximab combined with LMB-containing chemotherapy regimen has outstanding efficacy in ≤ 18-year-old patient with primary mediastinal large B-cell lymphoma!
Time of Update: 2022-11-15
Poke "Read Original" to see moreThe above results show that rituximab + LMB chemotherapy has good efficacy in PMBCL patients aged ≤ 18 years, with a 5-year EFS rate of 95.
-
European Radiology: imaging-based risk stratification enables prognostic assessment at the molecular level of diffuse glioma tissue
Time of Update: 2022-11-14
ROC curves of 1, 2, 3 and 5 years after surgery are providedIn this study, imaging-based risk stratification achieves a prognostic prediction of diffuse gliomas (NOS) at the tissue molecular level.
-
European Radiology: Enhanced ultrasound in the diagnosis of solid pancreatic lesions
Time of Update: 2022-11-14
Although the most common SPHL is pancreatic ductal adenocarcinoma (PDAC), both neuroendocrine tumors (NETs) and inflammatory lesions can exhibit similar clinical features[].
Although the most common SPHL is pancreatic ductal adenocarcinoma (PDAC), both neuroendocrine tumors (NETs) and inflammatory lesions can exhibit similar clinical features[].
-
J Clin Oncol: The circulating plasma cell threshold for primary plasma cell leukemia can be reduced to 2%!
Time of Update: 2022-11-14
The researchers evaluated CTC levels in 395 newly diagnosed transplant-ineligible MM patients by multiparametric flow cytometry to determine cut-off values for CTCs, thereby identifying ultra-high-risk PCL-like MM patients.
-
JAMA: More than 1/3 have had miscarriages, 1/3 have suffered discrimination, how difficult is it for female oncology doctors to give birth?
Time of Update: 2022-11-14
To this end, the purpose of this study was to (1) understand barriers to family planning in a person's career, (2) understand the association of fertility treatment options (such as ART) with career decisions, and (3) evaluate experiences of pregnancy-based discrimination among female oncologists.
-
STTT Review: ADC drug development history, challenges and next generation development directions
Time of Update: 2022-11-14
Antibody-drug conjugate (ADC) consists of a linker, payload, monoclonal antibody (mAb). It combines the advantages of high specific targeting ability and strong killing effect to achieve accurate and
-
Lilly CIIE joined hands with Ader Biologics and Ranshi Medical to help the new development of precision diagnosis and treatment of cancer in China
Time of Update: 2022-11-14
On November 6, at the 5th CIIE, Lilly reached a cooperation intention with Ader Biologics and Ranshi Medical to jointly promote the development of Lilly's world's first highly selective RET inhibitor, septitinib, for companion diagnostics in China, so as to benefit more RET-driven cancer patients in China.
-
PROTAC oral "rules"
Time of Update: 2022-11-14
The article exemplifies molecules, and summarizes the oral "rules" of PROTAC.
The article exemplifies molecules, and summarizes the oral "rules" of PROTAC.
The article exemplifies molecules, and summarizes the oral "rules" of PROTAC.
The article exemplifies molecules, and summarizes the oral "rules" of PROTAC.
-
AHA 2022: Extracellular vesicles in myocardial infarction promote tumor growth
Time of Update: 2022-11-14
Conclusion: We demonstrated for the first time that EVs secreted by cMSCs from infarction and remodeling the heart target tumor cells and promote tumor growth.
Conclusion: We demonstrated for the first time that EVs secreted by cMSCs from infarction and remodeling the heart target tumor cells and promote tumor growth.
-
Yangzheng depletion capsule was selected as the first postgraduate textbook of "Psychosocial Oncology" in China
Time of Update: 2022-11-14
In view of the important role of the motherland's medicine in the field of tumor symptom management, some traditional Chinese medicines widely used in clinical practice and supported by evidence-based medical evidence, such as Yangzheng depletion capsules, have also been written into this textbook.
-
Small Methods: Li Yaping's team at Shanghai Institute of Materia Medica, regulates nanoparticles through cholesterol metabolism to improve the effect of tumor photodynamic-immunotherapy
Time of Update: 2022-11-14
In this study, a matrix metalloproteinase (MMP-2)-responsive pro-osmotic nanoparticle was developed, which simultaneously regulated the cholesterol metabolism behavior of CTLs and tumor cells by promoting intratumoral penetration of drugs, improving the function of CTLs, and synergistically enhancing the anti-tumor effect of photodynamic-immunotherapy.
-
Lancet subjournal: Characteristics of circulating tumor DNA variation in aggressive breast lobular carcinoma
Time of Update: 2022-11-14
The researchers retrospectively analyzed data from 980 breast cancer patients with detailed clinical data (121 ILC, 972 IDC, and 62 mixed tissue types) and compared the single nucleotide variant (SNV), copy number variation (CNV) and oncogenic signaling pathway in the tissue samples.
